Month: March 2026

Nayax Partners with E-Plug, an Energy Plus NY Brand to Power Nationwide EV Charging Expansion with Integrated Payment and Charging Management Platform

Written by Customer Service on March 16, 2026. Posted in Public Companies.

Partnership combines Nayax’s payment technology with Lynkwell’s charging management platform, enabling Energy Plus to manage, monetize, and scale its US network from a single integrated solution HERZLIYA, Israel, March 16, 2026 (GLOBE NEWSWIRE) — Nayax Ltd. (Nasdaq: NYAX; TASE: NYAX), a global commerce enablement and payments platform designed to help merchants scale their business by simplifying payments and maximizing loyalty, today announced a strategic partnership with E-Plug, an Energy Plus NY (Energy Plus) brand, a fast-growing EV charging networks in the United States with approximately 2,200 connections, to support its continued nationwide expansion. As part of the partnership, Energy Plus has named Nayax as its preferred end-to-end solution provider, signing a long-term agreement to expand the deployment of...

SEALSQ Announces $125.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Written by Customer Service on March 16, 2026. Posted in Public Companies.

Geneva, Switzerland, March 16, 2026 (GLOBE NEWSWIRE) — Offering to be led by an affiliate of Heights Capital Management, Inc., and will consist of ordinary shares sold at $4.11 per share, accompanied by warrants with an exercise price of $5.50. SEALSQ Corp (NASDAQ: LAES) (“SEALSQ” or “Company”), a company that focuses on developing and selling Semiconductors, PKI and Post-Quantum technology hardware and software products, today announced that it has entered into a securities purchase agreement with several institutional investors to purchase 30,413,630 ordinary shares (or pre-funded warrants in lieu thereof) and accompanying warrants to purchase up to 60,827,260 ordinary shares priced at-the-market under Nasdaq rules (the “Offering”). The combined purchase price per ordinary share (or pre-funded warrant)...

SaverOne Expands Global Patent Portfolio with New European Patent Advancing its RF-Based Vehicle Safety Platform

Written by Customer Service on March 16, 2026. Posted in Public Companies.

This 15th granted patent reflects SaverOne’s technological leadership in identifying and managing mobile communication activity inside vehicles Petah Tikvah, Israel, March 16, 2026 (GLOBE NEWSWIRE) — SaverOne 2014 Ltd. (Nasdaq: SVRE, TASE: SVRE), a technology company specializing in advanced transportation safety and RF-based solutions, is pleased to announce that the European Patent Office (EPO) has granted the Company a new European patent (#EP4218305), entitled “A System Method and Unit to Scan Communication Channels.” The newly granted patent covers a method and system for scanning communication channels inside an enclosed space, such as a vehicle cabin, where there may be multiple mobile phones transmitting at the same time. The method allows a receiver to scan the detected frequencies, analyze the signals and set a dynamic...

JFB (NASDAQ: JFB) Announces XTEND and Rayonix Execute Exclusive Manufacturing and Distribution Agreement with Initial $11 Million Commitment to Expand XOS Platform into India.

Written by Customer Service on March 16, 2026. Posted in Public Companies.

XTENDXTEND and Rayonix Execute Exclusive Manufacturing and Distribution Agreement~ Exclusive Deal to Arm Rayonix’s India-Built UAVs with XOS ~ TAMPA BAY, Florida and NEW DELHI, India, March 16, 2026 (GLOBE NEWSWIRE) — JFB Construction Holdings (Nasdaq: JFB) and XTEND, a leader in software systems and AI-powered robotics, today announced XTEND has signed an $11 million manufacturing and distribution agreement with India-based defense technology company Rayonix Tech Private Limited to expand XTEND’s XOS autonomy platform into the Indian market. Under the agreement, Rayonix has been appointed XTEND’s exclusive manufacturing and distribution partner for selected XTEND platforms in India. The $11 million in payments and exclusive rights are subject to the satisfaction commercial performance milestones and regulatory compliance....

1847 Holdings Reports Preliminary Consolidated Unaudited 2025 Results with 207% Revenue Growth to $48.3 Million; Net Income and Adjusted EBITDA Reach $66.1 Million and $10.4 Million, Respectively

Written by Customer Service on March 16, 2026. Posted in Earnings Releases And Operating Results.

CMD Generated $40.5 Million in Preliminary Unaudited 2025 Revenue, Representing 32% Year-Over-Year Growth Compared with CMD’s Full-Year 2024 Pro Forma Revenue, Which Reflects the Full Year of CMD Operations for Comparability CMD’s Preliminary Unaudited 2025 Net Income was $6.9 Million, Compared to Pro Forma Net Income of $7.5 Million in the Prior Year, a 7% Year-Over-Year Decrease. Adjusted EBITDA Increased to $14.3 Million from $7.7 Million in the Prior Year on a Pro Forma Basis, a 84% Year-Over-Year Increase CMD Management Noted a Record Bid Pipeline Exceeding $160 Million Kyle’s Generated $6.6 Million in Preliminary Unaudited 2025 Revenue, Up 24% from $5.3 Million in 2024. Net Loss Increased to $1.3 Million from $1.0 Million in the Prior Year, While Adjusted EBITDA More Than Doubled $1.1 Million from $0.6 Million Preliminary Consolidated...

Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

Written by Customer Service on March 16, 2026. Posted in Earnings Releases And Operating Results.

Early clinical proof-of-concept for WEE1 inhibitor APR-1051 in the ongoing ACESOT-1051 trial with two partial responders at first scan in endometrial cancer patients with PPP2R1A mutation Clinical team strengthened with the appointment of Eugene (Gene) Kennedy, MD, as Chief Medical Advisor to support next phase of clinical development Capital is in place to support key milestones, including additional enrollment of patients at key dose levels in ongoing ACESOT-1051 trialDOYLESTOWN, Pa., March 16, 2026 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today reported financial results for the fourth quarter and full year ended December...

Lifecore Biomedical Reports Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, and Provides Corporate Update

Written by Customer Service on March 16, 2026. Posted in Earnings Releases And Operating Results.

— Recorded Fourth Quarter Revenues of $35.7 Million and Transition Period Revenues of $75.5 Million — — Multiple New Programs Signed in Fourth Quarter 2025 Including Two Commercial Site Transfer Programs, for Total of Five New Programs in 2025 Transition Period — — Organizational Initiatives Drive Further Improvement in Margins — Conference Call Today at 8:30am ET CHASKA, Minn., March 16, 2026 (GLOBE NEWSWIRE) — Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced strong results for the fourth quarter and transition period ended December 31, 2025. CEO Commentary “2025 was a highly productive year for Lifecore Biomedical, during which we strengthened our pipeline, leadership,...

LYB names David Dennison as head of investor relations; Dave Kinney to retire

Written by Customer Service on March 16, 2026. Posted in Dividend Reports And Estimates.

HOUSTON and LONDON, March 16, 2026 (GLOBE NEWSWIRE) — LyondellBasell (NYSE: LYB) today announced the appointment of David Dennison, a seasoned leader with decades-long service at LYB, as the new head of investor relations, effective May 8, 2026. He succeeds Dave Kinney, who will retire after nearly 35 years of service. “I am pleased to welcome David Dennison as our next head of investor relations,” said Agustin Izquierdo, executive vice president and chief financial officer. “His significant experience in global petrochemical markets will help us continue to shape investor understanding and foster clear, two-way engagement with the shareholder community.” David Dennison joined LYB in 2007, and in total brings nearly 30 years of industry experience to the role. He has held leadership roles across the company’s planning, commercial...

Extendicare Announces March 2026 Dividend of C$0.0441 per Share

Written by Customer Service on March 16, 2026. Posted in Dividend Reports And Estimates.

MARKHAM, Ontario, March 16, 2026 (GLOBE NEWSWIRE) — Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.0441 per common share of the Company for the month of March 2026, which is payable on April 15, 2026 to shareholders of record at the close of business on March 31, 2026. This dividend is designated as an “eligible dividend” within the meaning of the Income Tax Act (Canada). About Extendicare Extendicare is a leading provider of care and services for seniors across Canada, operating under the Extendicare, ParaMed, Extendicare Assist, and SGP Purchasing Network brands. We are committed to delivering quality care to meet the needs of the growing seniors’ population, inspired by our mission to provide people with the care they need, wherever they call home. We operate...

Monarch Private Capital Accelerates Impact in 2026 with Scaled Platforms and Disciplined Growth

Written by Customer Service on March 16, 2026. Posted in Dividend Reports And Estimates.

Investing Across Sectors to Deliver Community ImpactMonarch Private Capital’s investments support projects that strengthen communities nationwide—from utility-scale renewable energy and workforce housing to historic preservation and media infrastructure.ATLANTA, March 16, 2026 (GLOBE NEWSWIRE) — Monarch Private Capital, a national leader in tax equity impact investing, enters 2026 positioned for its next phase of disciplined growth—scaling proven platforms across energy, affordable housing, historic rehabilitation, and film while continuing to deliver predictable outcomes for investors and measurable benefits for communities nationwide. Impact at Scale Since 2005, Monarch has managed tax equity investments generating more than $9 billion in tax credits and supporting more than $23 billion in project development costs. These...

Month: March 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals